Patent classifications
A61L27/3873
Preparation and applications of biocompatible conductive inks based on cellulose nanofibrils for 3D printing of conductive biomedical devices and for use as models for study of neurodegenerative disorders and connection between brain/neurons and communication or other electronic devices
The present invention relates to preparation and use of nanocellulose fibrils or crystals such as disintegrated bacterial nanocellulose, tunicate-derived nanocellulose, or plant-derived nanocellulose, together with carbon nanotubes, as a biocompatible and conductive ink for 3D printing of electrically conductive patterns. Biocompatible conductive bioinks described in this invention were printed in the form of connected lines onto wet or dried nanocellulose films, bacterial cellulose membrane, or tunicate decellularized tissue. The devices were biocompatible and showed excellent mechanical properties and good electrical conductivity through printed lines (3.8.Math.10.sup.1 S cm.sup.1). Such scaffolds were used to culture neural cells. Neural cells attached selectively on the printed pattern and formed connective networks. The devices prepared by this invention are suited as bioassays to screen drugs against neurodegenerative diseases such as Alzheimer's and Parkinson's, study brain function, and/or be used to link the human brain with electronic and/or communication devices. They can also be implanted to replace neural tissue or stimulate guiding of neural cells. They can also be used to stimulate the heart by using electrical signaling or to repair myocardial infarction and/or damage related thereto.
CRYOPRESERVATION
Methods and materials for the cryopreservation of cellularised scaffolds used for therapeutic or pharmacological testing purposes that provide a cultured scaffold on which cells have been seeded, equilibrate the cellularised scaffold with a cryopreservative composition comprising culture medium and between 5 and 30% of a cryoprotectant such as DMSO, freeze the equilibrated cellularised scaffold by reducing the temperature continuously by about 1 C./minute to about 80 C., and store the frozen cellularised scaffold at a temperature of between 135 C. and 198 C.
Compositions for regenerating defective or absent myocardium
Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function.
DECELLULARIZED MUSCLE MATRIX
Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can be provided in a particulate form suitable for injection or implantation.
MYOCYTE-DERIVED FLOW ASSIST DEVICE: EXTRAVASAL SHEATHS OF RHYTHMICALLY CONTRACTING MYOCYTES AIDING FLOW OF BIOLOGICAL FLUIDS
This invention relates, e.g., to a Myocyte-based Flow Assist Device (MFAD) for treating a subject in need of increased flow of a biological fluid, such as venous blood or lymph, comprising a sheath which comprises rhythmically contracting myocytes.
Tissue use for repair of injury
The present disclosure describes methods of treating an injury in a subject using placental tissue streamers, engineered tissue placental tissue hybrids, suture placental tissue hybrids, placental tissue patch hybrids, and tissue hybrids, and the use of these compositions to repair, treat, or support an injury or degenerative process in a subject.
Surgically-friendly tissue papers from organ-specific decellularized extracellular matrices
Provided herein are inks including decellularized extracellular matrix (dECM) particles and scaffolds made from the inks. Also provided are methods of making the scaffolds and applications for the scaffolds. In an embodiment, a porous scaffold comprises dECM particles and an elastomer, wherein the scaffold is planar having a thickness of about 100 ?m or greater, the scaffold comprises irregularly shaped pores having a random orientation and distribution throughout the scaffold, and the scaffold is free of crosslinking between the molecular components of the scaffold.
Bioengineered vocal fold mucosa for functional voice restoration
An engineered vocal fold mucosa, including an engineered lamina propria layer and an engineered squamous epithelium layer, is disclosed. The engineered lamina propria is made by seeding and culturing human vocal fold fibroblasts within a polymerized collagen scaffold, and the engineered squamous epithelium is made by culturing human vocal fold epithelial cells on the scaffold surface. The resulting engineered vocal fold mucosa is not immunogenic, and is capable of exhibiting the vibratory function and acoustic output of a native vocal fold mucosa. Accordingly, the engineered vocal fold mucosa may be implanted into the larynx to treat voice impairment.
Three dimensional tissue compositions and methods of use
Engineered tissue compositions for supporting cell growth, maintenance, and/or differentiation featuring a scaffold, extracellular matrix (ECM) material, and optionally a population of ECM-generating cells such as fibroblasts. The tissue compositions may be used for supporting seeded cells of a particular cell type of interest such as cells related to skeletal muscle, smooth muscle, cardiac tissue, gastrointestinal tissue, etc. The tissue compositions with seeded cells may develop into functional tissues, which may have the potential to provide a tissue graft for therapeutic purposes or a valuable model for in vitro assays.
HUMAN CARDIAC TISSUE CONSTRUCT, RELATED METHODS AND USES
The present disclosure relates to a human cardiac tissue construct, to the method for producing thereof and its uses in disease modelling, compound screening and properties evaluation, and/or therapeutic uses in heart regeneration. It further relates to a perfusion bioreactor with electrical stimulation capabilities and its use in the production of said human cardiac tissue construct. In still a further aspect, the disclosure provides a method for the non-destructive evaluation of electrophysiological activity in a cellular construct, such as a cardiac tissue construct of the disclosure.